Canada Markets close in 4 hrs 29 mins

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.44+0.43 (+1.95%)
As of 11:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close22.01
Open22.44
Bid22.36 x 1000
Ask22.48 x 1200
Day's Range21.99 - 22.88
52 Week Range18.98 - 36.95
Volume127,358
Avg. Volume563,350
Market Cap1.792B
Beta (5Y Monthly)1.53
PE Ratio (TTM)28.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

    Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio

  • GlobeNewswire

    Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

    SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.

  • GlobeNewswire

    Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

    Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to st